Indication
Kidney Transplant Failure and Rejection
9 clinical trials
10 products
1 drug
Clinical trial
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationStatus: Completed, Estimated PCD: 2023-02-14
Product
ImlifidaseClinical trial
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal TransplantStatus: Active (not recruiting), Estimated PCD: 2025-07-30
Product
ClazakizumabClinical trial
An Adaptive Randomised Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney Pancreas Transplant RecipientsStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING StudyStatus: Recruiting, Estimated PCD: 2024-06-01
Product
GrafalonProduct
Normal TreatmentClinical trial
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced Natural Killer Cells Mediated (NK-mediated) RejectionStatus: Recruiting, Estimated PCD: 2027-12-03
Product
EverolimusClinical trial
A Single-armed, Unblinded, Non-randomized Feasibility Study of Hematopoietic Stem Cell Infusion Following a Conditioning Regimen of Total Lymphoid Irradiation (TLI) and Anti-thymocyte Globulin (ATG) in Patients With a Pre-existing, Well-functioning HLA-identical Kidney TransplantStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Cf-DNA Assay During Treatment of Acute Rejection-Pilot StudyStatus: Completed, Estimated PCD: 2023-09-05
Product
cf-DNAClinical trial
Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant RecipientsStatus: Recruiting, Estimated PCD: 2023-12-01
Product
EnvarsusDrug
Varlilumab